Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

the CONNECT MM Registry Investigators

doi:10.1111/bjh.17131

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect^® MM Registry

the CONNECT MM Registry Investigators

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Article › peer-review

Abstract

Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect^® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.

Original language	English (US)
Pages (from-to)	93-100
Number of pages	8
Journal	British journal of haematology
Volume	193
Issue number	1
DOIs	https://doi.org/10.1111/bjh.17131
State	Published - Apr 2021

Keywords

health-related quality of life
lenalidomide
multiple myeloma
real-world evidence

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.17131

Cite this

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect^® MM Registry. / the CONNECT MM Registry Investigators.
In: British journal of haematology, Vol. 193, No. 1, 04.2021, p. 93-100.

Research output: Contribution to journal › Article › peer-review

@article{7285ae959e5a43e6b3b1ffa0ba8abfa3,

title = "Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect{\textregistered} MM Registry",

abstract = "Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect{\textregistered} MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.",

keywords = "health-related quality of life, lenalidomide, multiple myeloma, real-world evidence",

author = "{the CONNECT MM Registry Investigators} and Rafat Abonour and Rifkin, {Robert M.} and Cristina Gasparetto and Kathleen Toomey and Durie, {Brian G.M.} and Hardin, {James W.} and Terebelo, {Howard R.} and Sundar Jagannath and Mohit Narang and Sikander Ailawadhi and Omel, {James L.} and Lee, {Hans C.} and Shankar Srinivasan and Amani Kitali and Amit Agarwal and Lynne Wagner",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd",

year = "2021",

month = apr,

doi = "10.1111/bjh.17131",

language = "English (US)",

volume = "193",

pages = "93--100",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent

T2 - results from the Connect® MM Registry

AU - the CONNECT MM Registry Investigators

AU - Abonour, Rafat

AU - Rifkin, Robert M.

AU - Gasparetto, Cristina

AU - Toomey, Kathleen

AU - Durie, Brian G.M.

AU - Hardin, James W.

AU - Terebelo, Howard R.

AU - Jagannath, Sundar

AU - Narang, Mohit

AU - Ailawadhi, Sikander

AU - Omel, James L.

AU - Lee, Hans C.

AU - Srinivasan, Shankar

AU - Kitali, Amani

AU - Agarwal, Amit

AU - Wagner, Lynne

PY - 2021/4

Y1 - 2021/4

N2 - Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.

AB - Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.

KW - health-related quality of life

KW - lenalidomide

KW - multiple myeloma

KW - real-world evidence

UR - http://www.scopus.com/inward/record.url?scp=85094665523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094665523&partnerID=8YFLogxK

U2 - 10.1111/bjh.17131

DO - 10.1111/bjh.17131

M3 - Article

C2 - 33118614

AN - SCOPUS:85094665523

SN - 0007-1048

VL - 193

SP - 93

EP - 100

JO - British journal of haematology

JF - British journal of haematology

IS - 1

ER -